内容紹介
Evaluation of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematological Malignancies Using MASCC Antiemesis Tool(MAT)
Summary
Chemotherapy-induced nausea and vomiting(CINV)were prospectively evaluated using MASCC Antiemesis Tool(MAT)in patients with hematological malignancies in our institution. A total of 33 patients receiving 46 chemotherapy courses were evaluated. Although vomiting was not observed in the acute phase, nausea was seen in 22.6% and 32.3% of the patients in the acute and delayed phases, respectively. Thirty percent(25 cases)of the patients receiving highly emetogenic chemotherapy presented nausea in both the phases, while 40%(18 cases)of the patients receiving moderately emetogenic chemotherapy presented nausea in the delayed phase. The oral intake was quantitated retrospectively in 31 patients with non-Hodgkin's lymphoma, who were hospitalized and received CHOP±R. Prior to the initiation of the chemotherapy, 13 patients received the first generation 5-HT3 receptor antagonist granisetron, while 18 patients received the second generation palonosetron. Oral intake was greater in the patients who were administered palonosetron. Thus, the present study suggested that antiemetic treatment could be improved at our institution.
要旨
今回われわれは,自施設での造血器悪性腫瘍に対する化学療法時の悪心・嘔吐をMASCC antiemesis tool(MAT)を用いて前向きに評価した。合計33例において46コースの化学療法が施行された。症例全体として,嘔吐は急性期,遅発期ともほとんどみられなかったが,悪心は急性期22.6%,遅発期に32.3%にみられた。高度催吐性化学療法施行例(25例)では悪心が急性期,遅発期とも約30%にみられた。中等度催吐性化学療法施行例(18例)の遅発性悪心が40%にみられた。CHOP±R療法においても約30%に悪心がみられた。入院にてCHOP±R療法第1コースが施行された31例において,制吐薬としてグラニセトロン(13例)とパロノセトロン(18例)の後方視的な比較では,食事摂取量はパロノセトロン症例で良好であった。血液領域における制吐療法は未だ改善の余地があり,前向き臨床研究による至適化が必要と考えられた。
目次
Summary
Chemotherapy-induced nausea and vomiting(CINV)were prospectively evaluated using MASCC Antiemesis Tool(MAT)in patients with hematological malignancies in our institution. A total of 33 patients receiving 46 chemotherapy courses were evaluated. Although vomiting was not observed in the acute phase, nausea was seen in 22.6% and 32.3% of the patients in the acute and delayed phases, respectively. Thirty percent(25 cases)of the patients receiving highly emetogenic chemotherapy presented nausea in both the phases, while 40%(18 cases)of the patients receiving moderately emetogenic chemotherapy presented nausea in the delayed phase. The oral intake was quantitated retrospectively in 31 patients with non-Hodgkin's lymphoma, who were hospitalized and received CHOP±R. Prior to the initiation of the chemotherapy, 13 patients received the first generation 5-HT3 receptor antagonist granisetron, while 18 patients received the second generation palonosetron. Oral intake was greater in the patients who were administered palonosetron. Thus, the present study suggested that antiemetic treatment could be improved at our institution.
要旨
今回われわれは,自施設での造血器悪性腫瘍に対する化学療法時の悪心・嘔吐をMASCC antiemesis tool(MAT)を用いて前向きに評価した。合計33例において46コースの化学療法が施行された。症例全体として,嘔吐は急性期,遅発期ともほとんどみられなかったが,悪心は急性期22.6%,遅発期に32.3%にみられた。高度催吐性化学療法施行例(25例)では悪心が急性期,遅発期とも約30%にみられた。中等度催吐性化学療法施行例(18例)の遅発性悪心が40%にみられた。CHOP±R療法においても約30%に悪心がみられた。入院にてCHOP±R療法第1コースが施行された31例において,制吐薬としてグラニセトロン(13例)とパロノセトロン(18例)の後方視的な比較では,食事摂取量はパロノセトロン症例で良好であった。血液領域における制吐療法は未だ改善の余地があり,前向き臨床研究による至適化が必要と考えられた。